SHR-A1201
SHR-A1201 is a HER2-targeting antibody-drug conjugate (ADC). SHR-A1201 is composed of a humanized anti-HER2 antibody , a linker SMCC (HY-42360), and a microtubulin inhibitor payload Mertansine (HY-19792). SHR-A1201 can be used for research in HER2-positive breast cancer[1].
Product Specifications
UNSPSC
12352203
Target
Antibody-Drug Conjugates (ADCs) ; EGFR
Type
Reference compound
Related Pathways
Antibody-drug Conjugate/ADC Related; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/shr-a1201.html
Purity
97.35
Smiles
S[R][A1201]
References & Citations
[1]Xianjing Li, et al. Development and validation of pharmacokinetics assays for a novel HER2-targeting antibody-drug conjugate (SHR-A1201) : Application to its dose-escalation pharmacokinetic study. J Pharm Biomed Anal. 2024 Mar 15:240:115964.
Shipping Conditions
Dry Ice
Storage Conditions
-80°C, protect from light
Badge
Hot
Scientific Category
ADC Related
Clinical Information
No Development Reported
Isoform
ErbB2/HER2
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
GTR15353482 1 Vial
Lentiviral human PPP1R3B shRNA (UAS) - Lentiviral human PPP1R3B shRNA (UAS) plasmid
Sign In for Pricing
View Details